2m 2m 2m 2m 2m 2m 2m
SUMMIT THERAP (SMMT)
NASDAQ
$14.25-$0.03 (-0.20%)
Price as of Jun 23, 2026 5:55 PM EDT- $11.1BMarket Cap
- -29.97%1-Year Change
- BiotechnologyIndustry
SUMMIT THERAP (SMMT)
$14.25-$0.03 (-0.20%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | 0 N/A | 0 -100.00% | 705,000 -61.03% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 N/A | 0 -100.00% | 705,000 -61.03% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -537.7M +256.60% | -150.8M +153.53% | -59.5M +14.37% | -52.0M -39.08% | |
Depreciation and Amortization Expense | 146,000 N/A | 0 N/A | 0 -100.00% | 914,000 -10.13% | |
Total Operating Expenses | 1.1B +383.59% | 226.3M -62.94% | 610.7M +600.21% | 87.2M -19.96% | |
Operating Profit | -1.1B +377.70% | -226.0M -62.93% | -609.6M +745.69% | -72.1M -16.36% | |
Interest Income | 15.5M +15.11% | 13.5M +29.44% | 10.4M +587.57% | 1.5M N/A | |
Interest Expense | 0 +100.00% | -8.7M -47.23% | -16.5M +274.03% | -4.4M +1,466.19% | |
Interest Income and Expense and Net | 15.5M +224.29% | 4.8M +178.90% | -6.1M +109.76% | -2.9M +927.76% | |
Total Nonoperating Income and Expense | 14.8M +10.99% | 13.4M +353.30% | -5.3M -21.14% | -6.7M +177.03% | |
Income before Taxes | -1.1B +377.70% | -226.0M -63.25% | -614.9M +680.54% | -78.8M -11.08% | |
Income Taxes | 0 N/A | N/A N/A | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -1.1B +387.81% | -221.3M -64.01% | -614.9M +680.54% | -78.8M -11.08% | |
Net Income from Continuing Operations Applicable to Common | -1.1B +387.81% | -221.3M -64.01% | -614.9M +680.54% | -78.8M -11.08% | |
Basic EPS and Net Income | -1.44 +364.52% | -0.31 -68.69% | -0.99 +141.46% | -0.41 -57.29% | |
Diluted EPS and Net Income | -1.44 +364.52% | -0.31 -68.69% | -0.99 +141.46% | -0.41 -57.29% | |
Basic Weighted Average Shares | 747.7M +4.06% | 718.5M +15.96% | 619.6M +220.50% | 193.3M +109.60% | |
Diluted Weighted Average Shares | 747.7M +4.06% | 718.5M +15.96% | 619.6M +220.50% | 193.3M +109.60% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 225.3M +114.82% | 104.9M +46.81% | 71.4M -79.51% | 348.6M +385.59% | |
Short-Term Investments | 488.2M +58.77% | 307.5M +167.81% | 114.8M N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 713.4M +73.02% | 412.3M +121.40% | 186.2M -46.58% | 348.6M +385.59% | |
Total Current Assets | 720.3M +69.98% | 423.8M +123.36% | 189.7M -71.11% | 656.7M +574.85% | |
Accumulated Depreciation | N/A N/A | 1.1M +7.29% | 1.0M -19.66% | 1.3M -61.59% | |
Property and Plant and Equipment and Net | 1.1M +316.93% | 254,000 +24.51% | 204,000 -77.48% | 906,000 +30.55% | |
Total Long-Term Assets | 7.2M +289.46% | 1.9M -57.20% | 4.3M +649.05% | 577,000 +239.41% | |
Total Assets | 751.2M +72.46% | 435.6M +114.62% | 202.9M -69.44% | 664.2M +485.82% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | 0 -100.00% | 19.8M N/A | |
Total Current Liabilities | 73.0M +74.91% | 41.7M +104.50% | 20.4M -47.39% | 38.8M +51.36% | |
Total Long-Term Debt | 0 N/A | 0 -100.00% | 100.0M -79.78% | 494.5M N/A | |
Total Long-Term Liabilities | 1.8M +12.39% | 1.6M +4.35% | 1.6M +9.31% | 1.4M -48.52% | |
Total Liabilities | 92.3M +97.22% | 46.8M -62.63% | 125.3M -76.70% | 537.5M +1,686.35% | |
Retained Earnings | -2.3B +88.89% | -1.2B +22.28% | -993.3M +162.54% | -378.3M +26.30% | |
Total Stockholders Equity | 658.9M +69.48% | 388.7M +400.37% | 77.7M -38.66% | 126.7M +52.07% | |
Total Shares Outstanding | 775.4M +5.12% | 737.6M +5.13% | 701.7M +232.40% | 211.1M +115.31% | |
Cash Flow | |||||
Cash from Operating Activities | -322.9M +127.25% | -142.1M +85.13% | -76.8M +84.60% | -41.6M -42.71% | |
Capital Expenditures | 657,000 +372.66% | 139,000 +8.59% | 128,000 -79.49% | 624,000 +103.92% | |
Cash from Investing Activities | -174.3M -15.11% | -205.3M -65.06% | -587.8M +94,094.55% | -624,000 +103.92% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 617.5M +61.99% | 381.2M +340.66% | 86.5M -86.05% | 620.2M +696.04% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | N/A N/A | -10,225.39% +114.63% | |
Return on Assets | -181.94% +162.46% | -69.32% -51.12% | -141.83% +599.91% | -20.26% -75.31% | |
Return on Equity | -206.10% +117.19% | -94.90% -84.23% | -601.85% +701.90% | -75.05% -31.07% | |
Revenue Growth | N/A N/A | N/A N/A | -100.00% +63.86% | -61.03% -155.30% | |
Current Ratio | 9.87 -2.82% | 10.15 +9.22% | 9.30 -45.09% | 16.93 +345.87% | |
Cash Ratio | 3.09 +22.82% | 2.51 -28.21% | 3.50 -61.06% | 8.99 +220.83% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | 1.29 -68.30% | 4.06 N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | 0.49 -36.38% | 0.77 N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow